In-vitro Studies for Solid Oral Dosage Forms in Pharma

Explore reference listed drug and generic drugs, their interchangeability and bioequivalence with brand-name products through in vitro studies, guided by the FDA Orange Book.

Explains drug development from basic research through nonclinical and clinical studies to NDA approval, highlighting in vitro and in vivo testing for reference listed drugs and generics, including bioequivalence testing.

Analyze in vitro and in vivo studies for solid oral dosage forms, detailing dissolution, bioavailability, and CTD dossier requirements for NDA/ANDA submissions.

Analyze how solubility in the gastrointestinal tract and permeability govern oral drug product performance, using the biopharmaceutical classification system to compare in vitro dissolution with in vivo absorption.

Explain how solubility drives dissolution in gastrointestinal fluids, detailing diffusion layer dynamics, absorption, and how in vitro dissolution tests predict in vivo performance for solid oral dosage forms.

Operate in vitro dissolution tests to observe drug release from solid oral dosage forms, using a six-vessel dissolution apparatus, sampling to assess concentration over time.

Explore how formulation components, excipients, and manufacturing parameters shape solubility and dissolution profiles of solid oral dosage forms, with emphasis on particle size, polymorphism, and method selectivity.

Explore how particle size distribution of low soluble API affects in vitro dissolution and solution performance, highlighting dissolution selectivity for solid oral dosage forms.

Investigate polymorphic structure as a critical material attribute affecting dissolution and solubility in solid oral dosage forms, and develop discriminative dissolution tests.

Explore how excipient composition influences in vitro dissolution and in vivo performance, focusing on disintegrant ratio effects on disintegration and dissolution profiles, and the need for selective dissolution testing.

Assess how critical process parameters, especially compression force, influence the solution characteristics and in vitro dissolution of solid oral dosage forms, and develop selective dissolution methods.

Use the dissolution method as a formulation development tool to design and select solid dosage forms with similar in vitro profiles to the reference product.

This dissolution method acts as a selective quality control tool to design formulations and ensure batch-to-batch consistency by detecting formulation, material, and process changes that affect dissolution and meet specs.

The dissolution method serves as a quality control tool. It is selective and discriminative to manufacturing parameter variations, with not less than 85% dissolution in 30 minutes.

Explore dissolution apparatus for solid oral dosage forms, comparing basket (apparatus one) and paddle, including agitation, sampling, and when to use sinkers to enclose dosage forms.

Explore stirring rate choices for solid oral dosage forms using basket or paddle apparatus, with basket at 100 rpm and paddle at 50–75 rpm, guided by method selectivity.

Explore how dissolution volume and sink condition influence the solution method for solid oral dosage forms, using 500–900 ml media to balance concentration for analysis and solubility-driven method development.

Design in vitro dissolution media to emulate gastric and intestinal conditions (pH 1.2, 4.5, 6.8) using acids and buffers, at least three media; justify surfactant use if needed.

Learn dissolution sampling with a cannula and filter to prevent undissolved solids, fix sampling points to avoid concentration gradients, and compare manual sampling with autosamplers for basket and paddle apparatus.

Identify and control critical dissolution parameters—volume, media content, apparatus, and temperature—while employing basket or paddle methods under multimedia conditions that mimic in vivo GI environments.

Assess dissolution results to compare reference listed drug and generic formulations using in vitro profiles and similarity factors f1 and f2.

Examine the selectivity and discriminative power of dissolution methods for solid oral dosage forms and how formulation changes, process parameters, and physico-chemical factors alter dissolution profiles.

Explore the selectivity of the dissolution method-2 for solid dosage forms by varying disintegrant levels in the unit formula and comparing dissolution profiles and similarity factors.

Evaluate the selectivity of a dissolution method by varying critical process parameters, specifically compression force, and demonstrate how hardness values affect solution profiles and method discrimination.

Explore how dissolution method selectivity detects changes in critical material attributes such as crystalline structure and particle size, enabling discriminative solubility assessment for solid oral dosage forms.

Develop and justify the dissolution method and solution profile, integrating solution method development with formulation development while addressing critical material attributes, critical process parameters, and CTD registration.

Develop robust, reproducible dissolution methods with discriminative power for quality control, selecting media, pH in physiological range, and surfactants, and optimizing paddle or basket conditions to reflect in vivo performance.

Explore how dissolution testing for solid oral dosage forms aligns with ICH, FDA, and EMA guidelines, distinguishing immediate, modified, and delayed release profiles and specifying single-point and multi-point dissolution criteria.

The lecture explains discriminative dissolution methods for immediate release tablets, defines solution specifications and solution test criteria, including time-based acceptance for highly soluble and slowly dissolving apis.